Royal DSM to invest $50M in Amyris, forge partnership
May 10, 2017
Biotechnology | Emeryville, CA | PIPE
Royal DSM (AEX: DSM) has taken a roughly 12% stake in Amyris (NASDAQ: AMRS) worth $25 million. The initial stake will double to $50 million in roughly three months, subject to Amyris satisfying certain benchmarks. The bioscience companies will also enter into a partnership focused on developing products for the global health and nutrition markets.